Long non-coding RNA signature in gastric cancer

被引:74
作者
Ghafouri-Fard, Soudeh [1 ]
Taheri, Mohammad [2 ]
机构
[1] Shahid Beheshti Univ Med Sci, Dept Med Genet, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Urogenital Stem Cell Res Ctr, Tehran, Iran
关键词
lncRNA; Gastric cancer; Expression; PROMOTES CELL-PROLIFERATION; COMPETING ENDOGENOUS RNA; PREDICTS POOR-PROGNOSIS; EPITHELIAL-MESENCHYMAL TRANSITION; HELICOBACTER-PYLORI INFECTION; UP-REGULATED EXPRESSION; DOWN-REGULATION; ABERRANT EXPRESSION; TUMOR-SUPPRESSOR; CHEMOTHERAPY RESISTANCE;
D O I
10.1016/j.yexmp.2019.104365
中图分类号
R36 [病理学];
学科分类号
100103 [病原生物学];
摘要
Gastric cancer as a common human malignancy has been associated with aberrant expressions of several coding and non-coding genes. Long non-coding RNAs (lncRNAs) as regulators of gene expressions at different genomic, transcriptomic and post-transcriptomic levels are among putative biomarkers and therapeutic targets in gastric cancer. In the present study, we have searched available literature and listed lncRNAs that are involved in the pathogenesis of gastric cancer. In addition, we discuss associations between expressions of these lncRNAs and tumoral features or risk factors for gastric cancer. Based on the established role of lncRNAs in regulation of genomic stability, cell cycle, apoptosis, angiogenesis and other aspects of cell physiology, the potential of these transcripts as therapeutic targets in gastric cancer should be evaluated in future studies.
引用
收藏
页数:26
相关论文
共 303 条
[1]
[Anonymous], 2017, COMBINATION CIRCULAT
[2]
[Anonymous], J CELL BIOCH
[3]
[Anonymous], SCI REP
[4]
[Anonymous], BMC COMPLEMENT ALTER
[5]
[Anonymous], CELL PHYSL BIOCH
[6]
[Anonymous], [No title captured]
[7]
[Anonymous], ONCOGENE
[8]
[Anonymous], LIFE SCI
[9]
Arita T, 2013, ANTICANCER RES, V33, P3185
[10]
Long noncoding RNA LINC00673 epigenetically suppresses KLF4 by interacting with EZH2 and DNMT1 in gastric cancer [J].
Ba, Ming-Chen ;
Long, Hui ;
Cui, Shu-Zhong ;
Gong, Yuan-Feng ;
Yan, Zhao-Fei ;
Wu, Yin-Bing ;
Tu, Yi-Nuo .
ONCOTARGET, 2017, 8 (56) :95542-95553